Brief: Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer
09/12/2025 13:41
Dec 9 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS PLC - ANNOUNCES PRECLINICAL DATA ON AKTX-101 FOR PANCREATIC CANCER AKARI THERAPEUTICS PLC - PLANS FIRST-IN-HUMAN TRIAL FOR AKTX-101 IN LATE 2026 Source text: ID:nGNX20w1Sb Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics